BioSpace News Archive

Syndax Pharmaceuticals, Inc. announced that it will release its second quarter 2019 financial results on Wednesday, August 7, after the close of the U.S. financial markets.

MDNA19 demonstrates robust efficacy and safety with or without checkpoint inhibitors in preclinical models; Clinical studies expected to commence in 2020

Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands

ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc.

United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2019.

Vendors in the market are increasingly focusing on the adoption of more targeted approaches such as anabolic medications for the effective treatment of the disease.

Theravance Biopharma, Inc. reported financial results for the second quarter ended June 30, 2019.

Rocket Pharmaceuticals, Inc., a leading U.S.-based multi-platform clinical-stage gene therapy company, announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, August 7, 2019, at 1:30p.m.

Hrusovsky, who will also share remarks at an investor dinner the prior evening hosted by Canaccord Genuity to discuss company momentum in advancing Alzheimer’s treatments and diagnoses, will also be available for one-on-one meetings during the conference.

FDA 510(k) cleared Respiration Rate analytic adds to physIQ’s growing portfolio of FDA 510(k) algorithms